Epilepsy, Attention-Deficit/Hyperactivity Disorder and Methylphenidate: Critical Examination of Guiding Evidence
Monidipa Ravi1, Abel Ickowicz1
1Department of Psychiatry, Hospital for Sick Children and University of Toronto, Toronto, Ontario.
Summary
Methylphenidate (MPH) appears safe for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in children with epilepsy, showing no increased seizure risk. MPH effectively improved ADHD symptoms, though study limitations exist.
Area of Science:
- Neuroscience
- Child Psychiatry
- Clinical Pharmacology
Background:
- Attention-Deficit/Hyperactivity Disorder (ADHD) and epilepsy frequently co-occur.
- Limited evidence exists on methylphenidate (MPH) safety and efficacy in comorbid ADHD and epilepsy.
- This review addresses the paucity of data to guide clinical practice.
Purpose of the Study:
- To critically appraise existing evidence on MPH treatment for ADHD in patients with seizure disorders.
- To inform management strategies for ADHD in the context of epilepsy.
Main Methods:
- Comprehensive literature search across major databases (Central, Embase, Medline, Web of Science).
- Identification and review of 349 references, selecting nine relevant studies.
- Detailed critical appraisal of seven prospective studies (including RCTs) and two retrospective reviews.
Main Results:
- No significant increase in seizure rates observed in most participants treated with MPH.
- MPH demonstrated efficacy in alleviating ADHD symptoms.
- Key limitations include small sample sizes, varied seizure types/severity, and inconsistent pre-treatment seizure-free periods.
Conclusions:
- A cautious approach to MPH use in children with stable epilepsy and ADHD symptoms is warranted.
- The benefits of treating ADHD symptoms should be weighed against potential risks.
- Further research with robust methodologies is needed to confirm findings.
More Related Videos
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
11.1K
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
6.6K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
1.3K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.3K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
812
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
812
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
1.1K
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
1.1K
01:24Epilepsy and Seizures: Overview
1.6K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
01:14Antiepileptic Drugs: Glutamate Antagonists
1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K